Company: CI
Filing Date: 2025-02-27
Form Type: 10-K
Source: 0001739940-25-000009
Chunk: 341

Company: Cigna Group
Filing Date: 2025-02-27
Form: 10-K
Item: Item 12
Chunk 341
---
Item 12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS

The following table presents information regarding The Cigna Group equity compensation plans as of December 31, 2024: (a) (1)(b) (2)(c) (3)Plan CategorySecurities To Be IssuedUpon Exercise ofOutstanding Options,Warrants and RightsWeighted AverageExercise Price ofOutstanding Options,Warrants and RightsSecurities RemainingAvailable for FutureIssuance Under EquityCompensation Plans(Excluding SecuritiesReflected in Column (a))Equity Compensation Plans Approved by Security Holders6,940,827 $226.38 12,386,735 Equity Compensation Plans Not Approved by Security Holders— — — Total6,940,827 $226.38 12,386,735 

(1)Includes, in addition to outstanding stock options:

(i) 51,563 restricted stock units, 34,006 deferred shares and 1,200,608 strategic performance shares that are reported at the maximum 200% payout rate granted under the Cigna Long-Term Incentive Plan and the Cigna Corporation Director Equity Plan; and 

(ii) 190,785 shares of common stock underlying stock option awards granted under the Express Scripts Holding Company 2016 Long-Term Incentive Plan, 171,987 shares of common stock underlying stock option awards granted under the Express Scripts, Inc. 2011 Long-Term Incentive Plan and 104,528 shares of common 

112

stock underlying stock option awards granted under the Medco Health Solutions, Inc. 2002 Stock Incentive Plan that were all approved by the applicable company's shareholders before acquisition of Express Scripts by The Cigna Group in December 2018.

(2)The weighted-average exercise price is based only on outstanding stock options. The outstanding stock options assumed due to the acquisition of Express Scripts by The Cigna Group, in aggregate, have a weighted-average exercise price of $151.37. Excluding the assumed options from this acquisition results in a weighted-average exercise price of $233.14.

(3)Represents 12,386,735 shares of common stock available as of the close of business December 31, 2024 for future issuance under the Cigna Long-Term Incentive Plan. No further grants may be made and no shares remain available for future issuance under any plan